Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
JACC: Heart Failure · 2023
DOI: 10.1016/j.jchf.2023.04.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2023. Verfasst von Jawad H Butt und 13 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Rigshospitalet Cop…. Hauptthemen laut MEDLINE: Heart Failure, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, AstraZeneca plc.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Heart failure (HF) is associated with impaired physical function and poor quality of life and affects health status more profoundly than many other chronic diseases. OBJECTIVES: The authors examined the effects of dapagliflozin on specific physical and social limitations as reported by patients in the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial. METHODS: The effect of dapagliflozin on the change from baseline to 8 months in each of the individual physical and social activity limitation questions answered by patients completing the Kansas City Cardiomyopathy Questionnaire (KCCQ), and overall scores, were examined with mixed-effects models and responder analyses. RESULTS: In total, 4,269 (90.0%) and 3,955 (83.4%) patients had complete data for both the physical and social activity limitation scores at baseline and 8 months, respectively. Compared with placebo, dapagliflozin significantly increased (improved) the mean KCCQ physical and social activity limitation scores at 8 months (placebo-corrected mean difference 1.94 [95% CI: 0.73-3.16] and 1.84 [95% CI: 0.43-3.25], respectively). Dapagliflozin also increased each of the individual components that comprise the physical and social activity limitations domains at 8 months, with the largest improvement seen in "hobbies or recreational activities" (placebo-corrected mean difference: 2.76 [95% CI: 1.06-4.46]) and "doing yardwork, housework, or carrying groceries" (placebo-corrected mean difference: 2.59 [95% CI: 0.76-4.42]). The proportion of patients with a 5-point improvement from baseline to 8 months in the KCCQ physical and social activity limitation scores was greater with dapagliflozin than with placebo (ORs: 1.23 [95% CI: 1.09-1.40] and 1.19 [95% CI: 1.05-1.35], respectively). CONCLUSIONS: In patients with HFrEF, dapagliflozin, compared with placebo, improved physical and social activity limitations as measured by KCCQ. (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure [DAPA-HF]; NCT03036124).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom; Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
- Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA.
- Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut, USA.
- Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
- Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Förderung
- British Heart Foundation
- AstraZeneca plc
Zitieren
APA
Butt, J. H., Docherty, K. F., Kosiborod, M. N., Inzucchi, S. E., Køber, L., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S., Jhund, P. S., & McMurray, J. J. V. (2023). Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2023.04.016
Vancouver
Butt JH, Docherty KF, Kosiborod MN, Inzucchi SE, Køber L, Langkilde AM, et al. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2023. doi:10.1016/j.jchf.2023.04.016
BibTeX
@article{Butt2023,
author = {Butt, Jawad H and Docherty, Kieran F and Kosiborod, Mikhail N and Inzucchi, Silvio E and Køber, Lars and Langkilde, Anna Maria and Martinez, Felipe A and Bengtsson, Olof and Ponikowski, Piotr and Sabatine, Marc S and Sjöstrand, Mikaela and Solomon, Scott and Jhund, Pardeep S and McMurray, John J V},
title = {Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2023},
doi = {10.1016/j.jchf.2023.04.016}
}
EUVIMED